

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway,
Goregaon (East), Mumbai – 400063 India
Tel. : (91-22) 43244324 / 1234
Fax.: (91-22) 43244343
CIN: L24230GJ1993PLC019050, www.sunpharma.com



January 18, 2019

National Stock Exchange of India Ltd,

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

NSE Code – SUNPHARMA

BSE Ltd,

Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.

BSE Code– 524715

Sub: Clarification /Confirmation on news item appearing in “Media/Publication”

Dear Sirs,

This is with reference to your email dated January 18, 2019 seeking clarification on the news item which appeared in the “Website-www.moneycontrol.com” dated January 18, 2019 captioned “Sun Pharma plummets over 12% over buzz of fresh whistleblower complaint”. In this regard we hereby submit our response as follows:

a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company.

Response: No, the Company has not received the alleged “172-page whistle blower complaint” and therefore we are not privy to the contents of the document being referred in the said media article. Hence, we cannot comment on the points being raised in the said media article.

Further, the said media article also refers to recall of Vecuronium Bromide Injection. We wish to clarify that one of the Company's 100% subsidiary has voluntarily recalled certain batches of Vecuronium Bromide Injection in the US market at hospital level due to identification of particulate matter identified as glass. This product has a negligible contribution to our Company's consolidated revenues and hence this recall will not have any material impact on our financials.

b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading? If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.

Response: No

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway,
Goregaon (East), Mumbai – 400063 India
Tel. : (91-22) 43244324 / 1234
Fax.: (91-22) 43244343
CIN: L24230GJ1993PLC019050, www.sunpharma.com



Kindly let us know in case you require any further clarification.

Yours faithfully,

For Sun Pharmaceutical Industries Limited,

A handwritten signature in blue ink, appearing to read "Sunil Ajmera", with a horizontal line underneath.

Sunil Ajmera
Company Secretary